A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4) (NCT05685238) | Clinical Trial Compass
Active — Not RecruitingPhase 3
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)
United States451 participantsStarted 2023-02-13
Plain-language summary
This study is looking at how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used to avoid bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). The study will last for up to 5.5 years. The duration of the study depends on when the participant enrolled in this study. The study will end if Mim8 is approved and marketed in participant's country during the study, or the study will end in June 2028, whichever comes first. Participants will get up to 262 injections; the number of injections depends on how often participants will get injections and how long time participants take part in the study. While taking part in this study, there are some restrictions about what medicine participants can use. The study doctor will tell the participants more about this. In case the participants experience bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor. Female participants cannot take part if they are pregnant, breast-feeding or plan to get pregnant during the study period.
Who can participate
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Informed consent obtained before any study related activities. Study related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
✓. Male or female with diagnosis of congenital haemophilia A based on medical records.
✓. Ongoing participation in study NN7769-4513, NN7769-4514, NN7769-4516, or NN7769-4728 at the time of transfer. Participant should qualify either of the following criteria:
✓. Participant from study NN7769-4513, who has participated in the extension part of the study for at least 12 weeks prior to enrolment in study NN7769-4532, or,
✓. Participant has completed the end of treatment visit for study NN7769-4514, NN7769-4516 or NN7769-4728.
✓. Participant and/or participant's parent(s)/participant's Legally acceptable representative (LAR) willingness and ability to comply with scheduled visits and study procedures, including the completion of diary.
Exclusion criteria
✕. Any disorder, except for conditions associated with haemophilia A, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
✕. Participant who has discontinued or been withdrawn from studies NN7769-4513, NN7769-4514, NN7769-4516, or NN7769-4728.
What they're measuring
1
Arm 1 and 2: Number of treatment emergent adverse events
Timeframe: From week 0 until end of study (up to 283 weeks)
2
Arm 3: Number of treatment emergent adverse events
Timeframe: From treatment initiation (week 0) until end of study (up to 124 weeks)
✕. Previous participation in this study. Participation is defined as signed informed consent.
✕. Female who is pregnant, breast-feeding or intends to become pregnant.
✕. Female of child-bearing potential and not using a highly effective contraceptive method (highly effective contraceptive measures or as required by local regulation or practice).
✕. Participation (i.e., signed informed consent) in any interventional, clinical study (except from study NN7769-4513, NN7769-4514, NN7769-4516, or NN7769-4728) of an approved or non-approved investigational medicinal product.
✕. Any planned major surgery, during part 1 of the study.
✕. Mental incapacity, unwillingness to cooperate, or a language barrier precluding adequate understanding and cooperation.